Regional overviews

celebrating 20 years Developed Europe

STATISTICS  
Number of products launched: 0 (2017: 0)#
IMS value of pipeline as at 30 June 2018 anticipated to be launched in:  
0 – 2 years USD0 million
3 – 5 years USD0 million
Number of product recalls: 7 (2017: 2)
Average staff turnover: 8,4% (2017: 9,7%)
Number of work-related fatalities: 0 (2017: 0)
Number of permanent employees:  
Number of permanent employees:  

#The number of product launches has been restated as a result of the refinement of the product launch definition.

 

Our Developed Europe business is made up of operations in Europe's major developed countries. The Anaesthetics and Thrombosis portfolios are the leading therapeutic focused brands in Developed Europe. The API site at Oss, supported by its satellite operation at Sioux City, supplies APIs worldwide. The Notre Dame de Bondeville and Bad Oldesloe sites are strategically important manufacturers for the Group.

KEY COUNTRIES

France, Germany, Italy, The Netherlands, United Kingdom

Contribution to Group revenue

Revenue - R'million 2018 2017 (CER) % change
Commercial Pharmaceuticals 7 434 6 941 7
Regional Brands 376 476 (21)
Anaesthetics 2 170 1 732 25
Thrombosis 3 471 3 204 8
High Potency & Cytotoxics 1 417 1 529 (7)
Manufacturing 4 895 4 930 (1)
– API 4 259 4 263 0
– FDF 636 667 (5)
Total 12 329 11 871 4

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture

 
  • Volumes of all products in the Developed Europe injectable anticoagulants category declined 1,5%. Aspen's share of the injectable anticoagulants category across Europe remained stable at 18% as at 30 May 2018.
  • The Anaesthetics category in Developed Europe grew 1,1% by value across all products to EUR1,3 billion as at 30 May 2018. General anaesthetics made up 50,3% of total value and grew 3,7% for the year.

Source: May 2018 IMS